Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.910
-0.020 (-1.04%)
At close: Mar 28, 2025, 4:00 PM
1.890
-0.020 (-1.05%)
Pre-market: Mar 31, 2025, 9:19 AM EDT
Akebia Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 51.87 | 42.93 | 90.47 | 149.8 | 228.7 | Upgrade
|
| Short-Term Investments | - | - | - | - | 39.99 | Upgrade
|
| Cash & Short-Term Investments | 51.87 | 42.93 | 90.47 | 149.8 | 268.69 | Upgrade
|
| Cash Growth | 20.84% | -52.55% | -39.61% | -44.25% | 81.92% | Upgrade
|
| Receivables | 34.37 | 39.29 | 40.28 | 55.89 | 28.58 | Upgrade
|
| Inventory | 16.24 | 15.69 | 21.57 | 36.63 | 61.02 | Upgrade
|
| Prepaid Expenses | 4.03 | 14.49 | 15.62 | 28.83 | 12.76 | Upgrade
|
| Restricted Cash | - | - | - | - | 0.4 | Upgrade
|
| Other Current Assets | 7.32 | 5.75 | 17.25 | - | - | Upgrade
|
| Total Current Assets | 113.83 | 118.15 | 185.18 | 271.15 | 371.44 | Upgrade
|
| Property, Plant & Equipment | 10.42 | 16.05 | 34.37 | 40.61 | 35.5 | Upgrade
|
| Goodwill | 59.04 | 59.04 | 59.04 | 59.04 | 55.05 | Upgrade
|
| Other Intangible Assets | - | 36.04 | 72.08 | 108.13 | 144.17 | Upgrade
|
| Other Long-Term Assets | 37.38 | 12.42 | 5.37 | 50.42 | 37.98 | Upgrade
|
| Total Assets | 220.67 | 241.7 | 356.05 | 529.35 | 644.14 | Upgrade
|
| Accounts Payable | 15.18 | 14.64 | 18.02 | 33.59 | 41.31 | Upgrade
|
| Accrued Expenses | 33.27 | 42.94 | 53.92 | 97.51 | 125.34 | Upgrade
|
| Current Portion of Long-Term Debt | 4.31 | 19.55 | 32 | 97.54 | - | Upgrade
|
| Current Portion of Leases | 5.4 | 4.49 | 4.74 | 4.8 | 5.29 | Upgrade
|
| Current Unearned Revenue | - | - | 3.74 | 20.91 | 15.21 | Upgrade
|
| Other Current Liabilities | 22.75 | 18.26 | 17.12 | 6.7 | - | Upgrade
|
| Total Current Liabilities | 80.91 | 99.87 | 129.54 | 261.05 | 187.15 | Upgrade
|
| Long-Term Debt | 175.47 | 111.29 | 91.56 | 53.08 | 96.38 | Upgrade
|
| Long-Term Leases | 3.55 | 8.95 | 28.96 | 33.7 | 24.62 | Upgrade
|
| Long-Term Unearned Revenue | - | 43.3 | 43.3 | 21.47 | 25.35 | Upgrade
|
| Other Long-Term Liabilities | 9.93 | 8.89 | 57.47 | 86.03 | 63.03 | Upgrade
|
| Total Liabilities | 269.86 | 272.29 | 350.82 | 455.34 | 396.52 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 1,629 | 1,578 | 1,562 | 1,537 | 1,425 | Upgrade
|
| Retained Earnings | -1,678 | -1,609 | -1,557 | -1,463 | -1,178 | Upgrade
|
| Comprehensive Income & Other | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Shareholders' Equity | -49.19 | -30.58 | 5.23 | 74.01 | 247.62 | Upgrade
|
| Total Liabilities & Equity | 220.67 | 241.7 | 356.05 | 529.35 | 644.14 | Upgrade
|
| Total Debt | 188.73 | 144.28 | 157.27 | 189.13 | 126.29 | Upgrade
|
| Net Cash (Debt) | -136.86 | -101.35 | -66.8 | -39.33 | 142.41 | Upgrade
|
| Net Cash Growth | - | - | - | - | 261.69% | Upgrade
|
| Net Cash Per Share | -0.65 | -0.54 | -0.37 | -0.24 | 1.03 | Upgrade
|
| Filing Date Shares Outstanding | 236.23 | 209.37 | 184.25 | 181.23 | 153.5 | Upgrade
|
| Total Common Shares Outstanding | 224.85 | 194.58 | 184.14 | 177 | 148.07 | Upgrade
|
| Working Capital | 32.92 | 18.28 | 55.65 | 10.1 | 184.29 | Upgrade
|
| Book Value Per Share | -0.22 | -0.16 | 0.03 | 0.42 | 1.67 | Upgrade
|
| Tangible Book Value | -108.23 | -125.67 | -125.9 | -93.16 | 48.4 | Upgrade
|
| Tangible Book Value Per Share | -0.48 | -0.65 | -0.68 | -0.53 | 0.33 | Upgrade
|
| Machinery | - | - | - | 5.85 | 5.79 | Upgrade
|
| Leasehold Improvements | - | - | - | 8.57 | 8.57 | Upgrade
|
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.